参考文献
 [1]  Yu CM， Lin H， Yang H， et al. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation， 2002， 105: 1195-1201.
 [2]  Yip G， Wang M， Zhang Y， et al. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart， 2002， 87: 121-125.
 [3]  Nikitin NP， Witte KK， Clark AL， et al. Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function. Am J Cardiol， 2002， 90: 1174-1177.
 [4]  Petrie MC， Caruana L， Berry C， et al. "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart， 2002， 87: 29-31.
 [5]  Bruch C， Gradaus R， Gunia S， et al. Doppler tissue analysis of mitral annular velocities: evidence for systolic abnormalities in patients with diastolic heart failure. J Am Soc Echocardiogr， 2003， 16: 1031-1036.
 [6]  Vinereanu D， Nicolaides E， Tweddel AC， et al. "Pure" diastolic dysfunction is associated with long-axis systolic dysfunction. Implications for the diagnosis and classification of heart failure. Eur J Heart Fail， 2005， 7: 820-828.
 [7]  Skaluba SJ， Litwin SE. Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation， 2004， 109: 972-977.
 [8]  Hadano Y， Murata K， Yamamoto T， et al. Usefulness of mitral annular velocity in predicting exercise tolerance in patients with impaired left ventricular systolic function. Am J Cardiol， 2006， 97: 1025-1028.
 [9]  Burlew BS， Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz， 2002， 27: 92-98.
 [10]  Schellings MW， Pinto YM， Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res， 2004， 64: 24-31.
 [11]  Maurer MS， El Khoury Rumbarger L， King DL. Ventricular volume and length in hypertensive diastolic heart failure. J Am Soc Echocardiogr， 2005， 18: 1051-1057.
 [12]  Sanderson JE， Chan SK， Chan WW， et al. The aetiology of heart failure in the Chinese population of Hong Kong--a prospective study of 730 consecutive patients. Int J Cardiol， 1995， 51: 29-35.
 [13]  Nicholls MG， Richards AM. Is hypertension a leading cause of heart failure in Chinese? Clin Exp Pharmacol Physiol， 2002， 29: 850-851.
 [14]  Harris KM， Spirito P， Maron MS， et al. Prevalence， clinical profile， and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation， 2006， 114: 216-225.
 [15]  Katz AM， Zile MR. New molecular mechanism in diastolic heart failure. Circulation， 2006， 113: 1922-1925.
 [16]  Gerdes AM. Cardiac myocyte remodeling in hypertrophy and progression to failure. J Card Fail， 2002， 8: S264-268.
 [17]  Kitzman DW， Little WC， Brubaker PH， et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. Jama， 2002， 288: 2144-2150.
 [18]  Brucks S， Little WC， Chao T， et al. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol， 2005， 95: 603-606.
 [19]  Zile MR， Gaasch WH， Carroll JD， et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation， 2001， 104: 779-782.
 [20]  van Heerebeek L， Borbely A， Niessen HW， et al. Myocardial structure and function differ in   systolic and diastolic heart failure. Circulation， 2006， 113: 1966-1973.
 [21]  Borbely A， van der Velden J， Papp Z， et al. Cardiomyocyte stiffness in diastolic heart failure.  Circulation， 2005， 111: 774-781.
 [22]  Makarenko I， Opitz CA， Leake MC， et al. Passive stiffness changes caused by upregulation of  compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res， 2004， 95: 708-716.
 [23]  Nagueh SF， Shah G， Wu Y， et al. Altered titin expression， myocardial stiffness， and left ventricular function in patients with dilated cardiomyopathy. Circulation， 2004， 110: 155-162.
 [24]  Neagoe C， Kulke M， del Monte F， et al. Titin isoform switch in ischemic human heart disease. Circulation， 2002， 106: 1333-1341.
 [25]  Ahmed SH， Clark LL， Pennington WR， et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural， functional， and clinical manifestations of hypertensive heart disease. Circulation， 2006， 113: 2089-2096.
 [26]  Heymans S， Schroen B， Vermeersch P， et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation， 2005， 112: 1136-1144.
 [27]  Spinale FG， Coker ML， Heung LJ， et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation， 2000， 102: 1944-1949.
 [28]  Owan TE， Hodge DO， Herges RM， et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med， 2006， 355: 251-259.
 [29]  Cleland JG， Tendera M， Adamus J， et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J， 2006， 27: 2338-2345.
 [30]  张运. 舒张性心力衰竭的研究进展. 心肺血管病杂志， 2004， 23: 51-57.
 [31]  Hogg K， Swedberg K， McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology， clinical characteristics， and prognosis. J Am Coll Cardiol， 2004， 43: 317-327.
 [32]  Bhatia RS， Tu JV， Lee DS， et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med， 2006， 355: 260-269.
 [33]  Lenzen MJ， Scholte op Reimer WJ， Boersma E， et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J， 2004， 25: 1214-1220.
 [34]  Vasan RS， Larson MG， Benjamin EJ， et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol， 1999， 33: 1948-1955.
 [35]  Mancini DM， Eisen H， Kussmaul W， et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation， 1991， 83: 778-786.
 [36]  Weber KT， Kinasewitz GT， Janicki JS， et al. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation， 1982， 65: 1213-1223.
 [37]  Cohen-Solal A， Laperche T， Morvan D， et al. Prolonged kinetics of recovery of oxygen consumption after maximal graded exercise in patients with chronic heart failure. Analysis with gas exchange measurements and NMR spectroscopy. Circulation， 1995， 91: 2924-2932.
 [38]  Pardaens K， Vanhaecke J， Fagard RH. Impact of age and gender on peak oxygen uptake in chronic heart failure. Med Sci Sports Exerc， 1997， 29: 733-737.
 [39]  Bittner V， Weine